Ownership and insider activity for Ascendis Pharma A/S (ASND): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates.
Price
| Price | $250.17 (closing price, November 3, 2026) |
| Market Cap | $16.5B |
| Exchange | NASDAQ |
| Country | DK |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-04-14 | BIENAIME JEAN JACQUES | A-Award | 9,160 | $2.3M |
| 2026-04-14 | BIENAIME JEAN JACQUES | D-Return | 9,160 | $1.6M |
| 2026-09-08 | Bodenhoff Mads | M-Exempt | 3,000 | $330K |
| 2026-09-08 | Bodenhoff Mads | M-Exempt | 3,000 | $330K |
| 2026-09-08 | Bodenhoff Mads | S-Sale | 3,000 | $811K |
| 2026-09-02 | HOLTUG LARS | S-Sale | 236 | $62K |
| 2026-08-14 | BIENAIME JEAN JACQUES | P-Purchase | 900 | $222K |
| 2026-08-14 | BIENAIME JEAN JACQUES | P-Purchase | 1,100 | $270K |
| 2026-06-02 | SMITH SCOTT THOMAS | P-Purchase | 100 | $22K |
| 2026-05-29 | BIENAIME JEAN JACQUES | P-Purchase | 100 | $22K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 180.3M EUR | 195.4M EUR | 277.9M EUR | 598.1M EUR | 584.5M EUR | 446.3M EUR | 444.8M EUR | 392.2M EUR | 559.5M EUR | 615.8M EUR |
| Short-term Investments | 0 | 0 | 0 | 0 | 134.3M EUR | 235.8M EUR | 290.7M EUR | 7.3M EUR | 0 | 0 |
| Receivables | 287,000 EUR | 188,000 EUR | 6,000 EUR | 804,000 EUR | 387,000 EUR | 2.2M EUR | 11.9M EUR | 35.9M EUR | 166.3M EUR | 157.6M EUR |
| Inventory | 0 | 0 | 0 | 0 | 0 | 75.4M EUR | 130.7M EUR | 208.9M EUR | 295.6M EUR | 301.4M EUR |
| Total Current Assets | 184.0M EUR | 204.6M EUR | 292.9M EUR | 611.2M EUR | 740.1M EUR | 805.9M EUR | 923.5M EUR | 702.7M EUR | 1.06B EUR | 1.11B EUR |
| Property, Plant & Equipment | 2.4M EUR | 2.6M EUR | 4.3M EUR | 45.1M EUR | 108.1M EUR | 126.0M EUR | 129.1M EUR | 110.6M EUR | 98.7M EUR | 146.4M EUR |
| Goodwill | 3.5M EUR | 3.5M EUR | 3.5M EUR | 3.5M EUR | 3.5M EUR | 3.5M EUR | 3.5M EUR | 3.5M EUR | 3.5M EUR | 3.5M EUR |
| Intangible Assets | 0 | 0 | 0 | 0 | 2.2M EUR | 1.8M EUR | 1.3M EUR | 924,000 EUR | 533,000 EUR | 214,907 EUR |
| Total Assets | 190.1M EUR | 211.0M EUR | 319.0M EUR | 676.7M EUR | 979.8M EUR | 1.08B EUR | 1.09B EUR | 825.6M EUR | 1.18B EUR | 1.30B EUR |
| Accounts Payable | 13.1M EUR | 17.4M EUR | 19.7M EUR | 27.8M EUR | 21.9M EUR | 59.4M EUR | 101.0M EUR | 94.6M EUR | 96.4M EUR | 90.6M EUR |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 7.0M EUR | 413.0M EUR | 421.3M EUR | 491.5M EUR | 486.3M EUR |
| Total Current Liabilities | 13.5M EUR | 23.8M EUR | 38.9M EUR | 48.0M EUR | 52.8M EUR | 100.4M EUR | 716.8M EUR | 736.5M EUR | 907.9M EUR | 1.07B EUR |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 98.0M EUR | 95.4M EUR | 223.0M EUR | 365.1M EUR | 385.1M EUR |
| Total Liabilities | 13.5M EUR | 23.8M EUR | 38.9M EUR | 79.6M EUR | 141.1M EUR | 201.3M EUR | 826.4M EUR | 971.3M EUR | 1.29B EUR | 1.46B EUR |
| Retained Earnings | -139.3M EUR | -263.2M EUR | -393.3M EUR | -611.3M EUR | -1.03B EUR | -1.24B EUR | -1.86B EUR | -2.28B EUR | -2.56B EUR | -2.70B EUR |
| Total Equity | 176.6M EUR | 187.2M EUR | 280.1M EUR | 597.1M EUR | 838.7M EUR | 883.6M EUR | 263.3M EUR | -145.7M EUR | -105.7M EUR | -162.8M EUR |
| Total Debt | 0 | 0 | 0 | 36.6M EUR | 92.0M EUR | 209.9M EUR | 617.6M EUR | 743.1M EUR | 856.6M EUR | 871.4M EUR |
| Net Debt | -180.3M EUR | -195.4M EUR | -277.9M EUR | -561.5M EUR | -626.8M EUR | -472.1M EUR | -117.9M EUR | 343.6M EUR | 297.1M EUR | 255.6M EUR |
| Working Capital | 170.5M EUR | 180.9M EUR | 254.0M EUR | 563.2M EUR | 687.3M EUR | 705.5M EUR | 206.7M EUR | -33.8M EUR | 153.0M EUR | 39.6M EUR |
Financial Health
| Debt / Equity | 0.31 |
| Current Ratio | 2.99 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 1.84 |
Profitability
| Return on Equity | 190.44% |
| Return on Invested Capital | 5.80% |
| Return on Assets | 33.08% |
| Gross Margin | 90.19% |
| Operating Margin | 10.38% |
| Net Margin | 71.69% |
Related companies: INSM · UTHR · NBIX · BMRN · CORT · MBX · SEPN
Explore sector: Healthcare · Biotechnology
More sections of ASND: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks